IQV — IQVIA Holdings Inc. stock price and chart

IQV

$271.55-0.75%

as of close, Oct 27, 2026

☾ AH $271.55 -0.75%

IQVIA Holdings Inc.Stock · HealthcareS&P 500 Equal Weight · 0.2% of RSPS&P 500 · 0.05% of SPYMSCI World · 0.05% of URTHRussell 1000 · 0.05% of IWBRussell 3000 · 0.04% of IWVUS Stock Market · 0.04% of VTIMSCI ACWI · 0.04% of ACWI

PeersAWATCRLMTDILMNIDXX

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEEEEEEEEEEEEEEEEEEEE

20162019202120242026

80.0100.0120.0140.0160.0180.0200.0220.0240.0260.0280.0020.0M40.0M$271.55

2026-10-27

Price$271.55

MA20$230.31

MA50$211.03

Vol6.4M

What would $1,000 invested in IQV be worth today? →

IQV returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $271.55
YTD price return: +20.47%
YTD total return: +20.47%
Market cap: 44.8B2016-12 18.7B2026-10 44.7B+138.9% over the window
Enterprise value: 59.1B
Shares outstanding: 164.8M2016-09 246.2M2026-09 164.8M-33.1% over the window
52W low: $154.50
52W high: $284.50
From 52W high: -4.55%
From 52W low: +75.76%
52W range: 90%
Beta: 1.17

Volume

Rel volume: 1.37×
30D volume: 1.5M
30D $ vol: 411.5M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1MNo open-market insider purchase or sale with a transaction date in the last 30 days, as filed on Form 4.: none
Insider net 3M0 insider-days of buying (no priced lot) and 3 of selling ($2.4M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$2.4M
Insider net 1Y0 insider-days of buying (no priced lot) and 6 of selling ($29.9M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$29.9M

Form 4 transactions by trade date, as filed; latest on file 2026-09-02.

Fundamentals

Sales (ttm): 17.3B2016-09 6.1B2026-09 17.3B+185.6% over the window
Sales/share: $105.042016-09 $24.622026-09 $105.04+326.6% over the window
EPS (ttm): $8.252016-09 $3.262026-09 $8.25+153.1% over the window
FCF (ttm): 2.1B2016-09 520.3M2026-09 2.1B+299.6% over the window
FCF/share: $12.622016-09 $2.112026-09 $12.62+496.9% over the window
Book value/share: $40.412016-09 -$1.272026-09 $40.41-3274.2% over the window
Net margin: 8.05%2016-09 6.6%2026-09 8.1%+22.6% over the window
ROE: 20.93%2016-12 0.8%2026-09 20.9%+2409.7% over the window
ROA: 4.57%2016-09 9.6%2026-09 4.6%-52.5% over the window
Debt / equity: 2.23×2016-12 0.822026-09 2.23+170.3% over the window
Current ratio: 0.832016-09 1.632026-09 0.83-49.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +8.85%2025-09-30 → 2026-09-3015.9B → 17.3B (+8.8% total)+5.23%2023-09-30 → 2026-09-3014.9B → 17.3B (+16.5% total)+5.04%2021-09-30 → 2026-09-3013.5B → 17.3B (+27.9% total)+11.07%2016-09-30 → 2026-09-306.1B → 17.3B (+185.6% total)
Net income: +8.66%2025-09-30 → 2026-09-301.3B → 1.4B (+8.7% total)+7.69%2023-09-30 → 2026-09-301.1B → 1.4B (+24.9% total)+12.69%2021-09-30 → 2026-09-30767M → 1.4B (+81.7% total)+13.36%2016-09-30 → 2026-09-30398M → 1.4B (+250.3% total)
FCF: -5.97%2025-09-30 → 2026-09-302.2B → 2.1B (-6.0% total)+16.31%2023-09-30 → 2026-09-301.3B → 2.1B (+57.4% total)-2.57%2021-09-30 → 2026-09-302.4B → 2.1B (-12.2% total)+14.86%2016-09-30 → 2026-09-30520.3M → 2.1B (+299.6% total)
Shares: -3.23%2025-09-30 → 2026-09-30170.3M → 164.8M (-3.2% total)-3.34%2023-09-30 → 2026-09-30182.5M → 164.8M (-9.7% total)-2.91%2021-09-30 → 2026-09-30191M → 164.8M (-13.7% total)-3.93%2016-09-30 → 2026-09-30246.2M → 164.8M (-33.1% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +13.03%2025-09-30 → 2026-09-30$7.30 → $8.25 (+13.0% total)+11.46%2023-09-30 → 2026-09-30$5.96 → $8.25 (+38.5% total)+15.93%2021-09-30 → 2026-09-30$3.94 → $8.25 (+109.4% total)+9.73%2016-09-30 → 2026-09-30$3.26 → $8.25 (+153.1% total)
Sales/share: +12.49%2025-09-30 → 2026-09-30$93.39 → $105.04 (+12.5% total)+8.87%2023-09-30 → 2026-09-30$81.40 → $105.04 (+29.0% total)+8.19%2021-09-30 → 2026-09-30$70.85 → $105.04 (+48.3% total)+15.62%2016-09-30 → 2026-09-30$24.62 → $105.04 (+326.6% total)
FCF/share: -2.83%2025-09-30 → 2026-09-30$12.98 → $12.62 (-2.8% total)+20.34%2023-09-30 → 2026-09-30$7.24 → $12.62 (+74.3% total)+0.35%2021-09-30 → 2026-09-30$12.40 → $12.62 (+1.8% total)+19.56%2016-09-30 → 2026-09-30$2.11 → $12.62 (+496.9% total)
Book value/share: +11.73%2025-09-30 → 2026-09-30$36.17 → $40.41 (+11.7% total)+8.31%2023-09-30 → 2026-09-30$31.81 → $40.41 (+27.1% total)+5.78%2021-09-30 → 2026-09-30$30.51 → $40.41 (+32.4% total)n/a
Price: +24.91%2025-10-27 → 2026-10-27$217.43 → $271.55 (+24.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+14.70%2023-10-27 → 2026-10-27$179.94 → $271.55 (+50.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+1.32%2021-10-27 → 2026-10-27$254.29 → $271.55 (+6.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+14.02%2016-10-26 → 2026-10-27$73.12 → $271.55 (+271.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +24.91%2025-10-27 → 2026-10-27$217.43 → $271.55 (+24.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+14.70%2023-10-27 → 2026-10-27$179.94 → $271.55 (+50.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+1.32%2021-10-27 → 2026-10-27$254.29 → $271.55 (+6.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+14.02%2016-10-26 → 2026-10-27$73.12 → $271.55 (+271.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 32.9×2016-12 47.042026-10 32.08-31.8% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 20.2×2016-12 27.702026-10 20.16-27.2% over the window
Fwd P/E: 19.4×
P/S (ttm)Market cap ÷ TTM revenue.: 2.6×2016-12 3.092026-10 2.58-16.4% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 6.7×2016-12 -59.732026-10 6.72-111.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 21.5×2016-12 35.982026-10 21.51-40.2% over the window
EV/EBITDA (fy): 17.2×
EV/Sales (ttm): 3.4×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 4.65%2016-09 2.8%2026-09 4.7%+68.8% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-09-30) ÷ shares_at(2025-09-30) = 1 − 164.8M ÷ 170.3M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 3.23%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (3.23%) + dividends paid over that year ($0) ÷ market_cap_at(2025-09-30) ($32.3B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 3.23%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($1.2B) ÷ today's market cap ($44.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.60%2016-09 1.9%2026-09 2.6%+35.3% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $1.2B + TTM dividends $0) ÷ today's market cap ($44.8B). Same caveat as the cash buyback yield.: 2.60%2016-09 1.9%2026-09 2.6%+35.3% over the window

Vs own 10Y history

P/E: 38th
P/OI: 26th
P/S: 45th
P/B: 76th
P/FCF: 28th

Bar = where today’s multiple sits in IQV’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-27#

-0.75%

+1.38%

+0.44%

+27.36%

YTD

+20.47%

+24.89%

+6.79%

Recent filings#

Oct 27Earnings · Earnings release — EPS $2.73 vs $2.94 est.; revenue $4.43B (+8% y/y) 0.7%
Sep 98-K · IQVIA Announces Offering of Senior Notes
Sep 2Insider sale · Berkshire James G. (See Remarks) sold 2,668 shares for $697K at $261.33
Aug 3Insider sale · STAUB W RICHARD (See Remarks) sold 5,500 shares for $1.3M at $232.68
Jul 31Insider sale · Patel Bhavik (See Remarks) sold 1,855 shares for $436K at $235.27

All filings and insider trades →

Financial statements

Open full IQV financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+8.32%	+0.22%
JNJ	Johnson & Johnson	-0.92%	+0.91%
ABBV	AbbVie Inc.	+8.34%	-0.12%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+8.98%	-0.08%
MRK	Merck & Co. Inc.	-4.68%	+0.86%
NVS	Novartis AG	+7.84%	+1.98%
TMO	Thermo Fisher Scientific Inc.	+2.67%	+1.19%
AMGN	Amgen Inc.	+8.04%	+0.75%

IQV — IQVIA Holdings Inc. price, chart and key statistics